ACI Formulations (DHA:ACIFORMULA) Total Operating Expense: BDT1,070 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

DHA:ACIFORMULA ACI Formulations PLC DHA:ACIFORMULA
88 GF Score
Price BDT172.00
GF Value BDT149.48
Valuation Modestly Overvalued
! 8 Warning Signs
View Full Analysis

What is ACI Formulations Total Operating Expense?

ACI Formulations DHA:ACIFORMULA +1.42% 88 Total Operating Expense is BDT1,070 Mil as of Mar. 2026. GuruFocus rates DHA:ACIFORMULA with a GF Score™ of 88/100 and a GF Value™ of BDT149.48 (Modestly Overvalued). The stock has 8 warning signs investors should review.

ACI Formulations's Total Operating Expense for the three months ended in Mar. 2026 was BDT264 Mil. ACI Formulations's Total Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 was BDT1,070 Mil.

ACI Formulations Total Operating Expense Related Terms

ACI Formulations Total Operating Expense Historical Data

* Premium members only.

The historical data trend for ACI Formulations's Total Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ACI Formulations Total Operating Expense Chart

ACI Formulations Annual Data
Trend Dec15 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Total Operating Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 710.35 769.02 822.59 849.80 945.09

ACI Formulations Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 232.49 275.95 244.68 285.76 263.76
DHA:ACIFORMULA
88GF Score
ACI Formulations PLC DHA:ACIFORMULA
Total Operating Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

ACI Formulations Total Operating Expense Calculation

Total Operating Expense is the primary recurring expense associated with central operations that are incurred in order to generate sales.


Total Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was BDT1,070 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Total Operating Expense of BDT1,070 Mil mean?
ACI Formulations (DHA:ACIFORMULA) has a Total Operating Expense of BDT1,070 Mil as of Mar. 2026. Total operating expense is the primary recurring expense associated with central operations. View historical data on ACI Formulations and its competitors.
Is ACI Formulations' Total Operating Expense too high?
ACI Formulations' current Total Operating Expense is BDT1,070 Mil. Overall, ACI Formulations has a GF Score™ of 88/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does ACI Formulations' Total Operating Expense compare to CTVA and CF?
ACI Formulations' Total Operating Expense of BDT1,070 Mil can be compared against companies in the Agriculture industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Operating Expense for an Agriculture company?
A good Total Operating Expense depends on the Agriculture industry context. However, Total Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Operating Expense mean?
A high Total Operating Expense can signal that a stock is expensive relative to its fundamentals. Total operating expense is the primary recurring expense associated with central operations. View historical data on ACI Formulations and its competitors. ACI Formulations's current Total Operating Expense is BDT1,070 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ACI Formulations stock overvalued right now?
Based on GuruFocus' analysis, ACI Formulations (DHA:ACIFORMULA) is currently considered Modestly Overvalued. The stock's GF Value™ is BDT149.48, compared to a current price of BDT172.00 — trading 15.1% above its estimated fair value. The current Total Operating Expense is BDT1,070 Mil. ACI Formulations' overall GF Score™ is 88/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Operating Expense calculated?
Total Operating Expense is calculated from a company's financial statements. For ACI Formulations (DHA:ACIFORMULA), the current Total Operating Expense is BDT1,070 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is ACI Formulations (DHA:ACIFORMULA) Overvalued in 2026?

Based on GuruFocus' analysis, ACI Formulations stock appears to be overvalued. The current stock price of BDT172.00 is trading 15.1% above its estimated GF Value™ of BDT149.48. GuruFocus considers ACI Formulations to be Modestly Overvalued.

Key valuation signals for DHA:ACIFORMULA:

  • Total Operating Expense: BDT1,070 Mil
  • GF Value™: BDT149.48 vs. price of BDT172.00 (15.1% above fair value)
  • GF Score™: 88/100 with 8 warning signs

No single metric tells the full story. See the DHA:ACIFORMULA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

ACI Formulations Business Description

Address ACI Centre, 245, Tejgaon Industrial Area, Dhaka, BGD, 1208
ACI Formulations PLC is engaged in the manufacturing and marketing of several agrochemical and consumer products. The company offers a complete range of cost-effective solutions for farmers through formulating and marketing insecticides, herbicides, fungicides, miticides, etc. Its businesses are Pharmaceuticals, Salt, Skincare & Antiseptics, Kitchen Care, Fabric Care, Surface Care, Herbal Care, Lavatory Care, and Others. The group's reportable segments are Crop Care and Public Health (CC & PH), which include manufacturing and selling crop care and public health products; Mosquito coil (M. Coil) includes manufacturing and selling mosquito coil products; Aerosol provides manufacturing and selling aerosol and air freshener products; and Paint covers manufacture and sell paint products.
88GF Score

Get the complete analysis for DHA:ACIFORMULA

Total Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

BDT172.00
Price
BDT149.48
GF Value